<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403949</url>
  </required_header>
  <id_info>
    <org_study_id>1400418</org_study_id>
    <secondary_id>2006-002471-40</secondary_id>
    <nct_id>NCT00403949</nct_id>
  </id_info>
  <brief_title>A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis</brief_title>
  <official_title>A 6-week, Vehicle-controlled, Randomized, Double-blind, Parallel-group Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Perioral Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy and safety of AzA 15% Gel in the treatment
      of mild to moderate perioral dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sum score derived from the most important signs and symptoms of perioral dermatitis</measure>
    <time_frame>Measurements and observations during the course of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of single signs and symptoms</measure>
    <time_frame>Measured at scheduled visits during the course of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes measures will be all adverse events reported by the patients or observed by the investigator</measure>
    <time_frame>Safety parameters recorded at scheduled visits during the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Perioral Dermatitis</condition>
  <arm_group>
    <arm_group_label>Azelaic acid 15% Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azelaic acid 15%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-active base from Azelaic acid 15% gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid 15% gel</intervention_name>
    <description>gel, applied once daily, for 6 weeks</description>
    <arm_group_label>Azelaic acid 15% Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-active base from azelaic acid 15% gel</intervention_name>
    <description>gel, apply once daily for six weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of mild to moderate perioral dermatitis as diagnosed by the
             physician

          -  Investigator's Global Assessment (IGA) score at baseline of 2 or 3 (on scale from 0 to
             4)

          -  8 to 50 facial inflammatory lesions (papules, papulopustules, papulovesicles)

        Exclusion Criteria:

          -  History of atopic dermatitis of the face

          -  Granulomatous perioral dermatitis

          -  Facial acne, rosacea, facial demodicosis

          -  Seborrheic dermatitis of the nasolabial fold, Lupus erythematosus

          -  The use of topical or systemic medications that could affect the course of treatment
             and/or evaluation

          -  Severe diseases likely to interfere with the conduct / planned termination of the
             study (e.g. cancer, cardiac infarct, unstable angina pectoris, uncontrolled diabetes)

          -  Use of fluorinated toothpaste

          -  Planned exposure to artificial or intensive natural UV light of the test area
             throughout the course of the study

          -  Use / planned use of cosmetic products (e.g. creams, moisturizers, make-up, fatty
             lipstick) in the test area during the course of the study

          -  History of or suspected hypersensitivity to any ingredient of the study drugs

          -  Participation in another clinical study 4 weeks prior to and/or during the conduct of
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DÃ¼lmen</city>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recklinghausen</city>
        <zip>45661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2006</study_first_submitted>
  <study_first_submitted_qc>November 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>February 15, 2015</last_update_submitted>
  <last_update_submitted_qc>February 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Perioral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

